Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by interacting with the 50S subunit of the bacterial ribosome. Its antibacterial activity depends on its ability to interfere with the cellular machinery responsible for producing proteins essential for bacterial growth, maintenance, and replication. By disrupting this process, erythromycin limits the capacity of susceptible bacteria to synthesize functional proteins required for normal cellular activity. This mechanism distinguishes erythromycin from antibiotics that primarily target bacterial cell wall synthesis, nucleic acid replication, or membrane integrity.
The macrolide class includes several antibiotics with related structural characteristics and mechanisms of action. Azithromycin and clarithromycin are prominent examples that share important pharmacological properties with erythromycin. Although these agents belong to the same antibiotic family, differences in their chemical structures influence their pharmacokinetic characteristics, antimicrobial spectrum, tolerability, and potential for drug interactions. Individual macrolides may have different clinical applications despite their common capacity to inhibit bacterial protein synthesis.
The bacterial ribosome is a complex molecular structure composed of ribosomal RNA and associated proteins. It consists of two principal subunits, designated 30S and 50S, which work together during translation to convert genetic information carried by messenger RNA into polypeptide chains. The 50S subunit participates in peptide bond formation and the coordinated movement of transfer RNA molecules through the ribosome. These processes are essential for the progressive elongation of newly synthesized proteins.
Erythromycin exerts its principal effect by binding to a specific region of the 23S ribosomal RNA within the 50S subunit. This interaction interferes with the normal progression of translation, particularly the translocation step, during which the ribosome advances along the messenger RNA template. By obstructing this movement, erythromycin impairs the orderly progression of protein synthesis and reduces the production of proteins necessary for bacterial proliferation. The resulting effect is generally bacteriostatic, meaning that the antibiotic inhibits bacterial growth rather than directly killing the microorganisms under typical susceptible conditions. The observed activity may vary according to the bacterial species, drug concentration, and surrounding conditions.
Other antibiotics also interfere with bacterial protein synthesis but belong to different pharmacological groups. Clindamycin and lincomycin, for example, are lincosamide antibiotics that act on the 50S ribosomal subunit. Despite similarities in their molecular targets and effects on translation, they are classified separately from macrolides because of differences in chemical structure and pharmacological characteristics. Their overlapping mechanisms may also have implications for antimicrobial susceptibility and resistance patterns.
The effectiveness of erythromycin is influenced by the susceptibility of the target organism and the ability of the drug to reach an effective concentration at the site of infection. Bacterial resistance can develop through mechanisms such as modification of the ribosomal binding site, reduced intracellular drug accumulation, or active drug efflux. These mechanisms can diminish the interaction between erythromycin and its target, thereby reducing antibacterial activity.
Sources of erythromycin
Erythromycin is a macrolide antibiotic produced naturally through microbial biosynthesis by specific actinomycetes belonging to the genus Saccharopolyspora. Historically, erythromycin production was associated with Streptomyces erythreus, the original name for the organism now classified as Saccharopolyspora erythraea. This filamentous, soil-associated bacterium produces erythromycin as a secondary metabolite during its growth and development. The discovery of this microorganism established an important foundation for the industrial production of erythromycin and the subsequent development of structurally related macrolide antibiotics.
Natural erythromycin biosynthesis involves a complex sequence of enzymatic reactions regulated by the microorganism’s genetic machinery. The biosynthetic pathway begins with the assembly of a polyketide backbone through the action of modular polyketide synthase enzymes. These enzymes utilize precursor molecules, including propionyl-CoA and methylmalonyl-CoA, to construct the characteristic 14-membered lactone ring of erythromycin. Subsequent enzymatic reactions introduce sugar components, including desosamine and cladinose, which contribute to the antibiotic’s biological activity and physicochemical properties. The coordinated activity of biosynthetic enzymes determines the final molecular structure and influences the relative abundance of erythromycin congeners produced during fermentation.
Industrial erythromycin production primarily relies on controlled microbial fermentation. During this process, selected strains of Saccharopolyspora erythraea are cultivated under carefully regulated conditions involving nutrient availability, temperature, pH, aeration, and agitation. Optimizing these parameters supports microbial growth and promotes antibiotic biosynthesis. Following fermentation, erythromycin is recovered from the culture medium or associated biomass, depending on its distribution within the production system. Downstream processing generally involves extraction, purification, concentration, and crystallization to obtain material that meets the required quality specifications for pharmaceutical applications. Process efficiency depends on strain characteristics, fermentation conditions, product stability, and the effectiveness of purification procedures.
In addition to natural biosynthesis, modifications of the erythromycin structure have contributed to the development of semisynthetic macrolides. Chemical or enzymatic approaches can alter selected positions within the parent molecule, including functional groups associated with the macrolactone ring and its attached sugars. Such structural modifications can influence acid stability, absorption, tissue distribution, antimicrobial activity, and susceptibility to bacterial resistance mechanisms. Azithromycin and clarithromycin are important examples of later-generation macrolides developed through structural modification of erythromycin-related compounds. Although these antibiotics share structural and pharmacological characteristics with erythromycin, their distinct molecular features produce differences in their clinical properties.
Structure of erythromycin
Erythromycin is a macrolide antibiotic characterized by a large macrocyclic lactone ring attached to two sugar residues through glycosidic linkages (Figure 1). Its molecular architecture is fundamental to its physicochemical properties, ribosomal binding affinity, and antibacterial activity. Unlike antibiotics that contain compact heterocyclic frameworks, erythromycin possesses a relatively large, flexible ring system that provides the structural foundation for its interaction with the bacterial ribosome.
The core structure of erythromycin consists of a 14-membered lactone ring known as erythronolide, which contains multiple hydroxyl groups and carbonyl functionality (Figure 2). These functional groups contribute to the molecule’s polarity, hydrogen-bonding capacity, and conformational characteristics. The lactone ring is essential to maintaining the three-dimensional arrangement required for biological activity. Substitutions and chemical modifications within this framework can influence molecular stability, solubility, and interactions with biological targets.
Two distinct sugar components are attached to the macrocyclic ring: desosamine and cladinose. Desosamine is an amino sugar that contains a dimethylamino group, which contributes to the basic character of erythromycin and plays an important role in its interaction with the bacterial ribosomal binding site. Cladinose, a neutral deoxy sugar, is attached at a separate position on the lactone ring and contributes to the molecule’s overall structural configuration. Both sugars are connected to the macrocycle through O-glycosidic bonds, forming an integrated molecular structure in which the lactone ring and carbohydrate substituents collectively determine antibiotic activity.
The spatial orientation of these structural components facilitates erythromycin binding to the 50S subunit of the bacterial ribosome, particularly within the nascent peptide exit tunnel. This interaction interferes with bacterial protein synthesis and consequently suppresses microbial growth. The functional importance of the sugar residues and the configuration of the macrocyclic ring explains why structural alterations can affect antimicrobial potency and susceptibility to chemical degradation.
Clinical application of erythromycin
Erythromycin is a macrolide antibiotic employed in the management of selected bacterial infections caused by susceptible microorganisms (Figure 3). Its clinical utility is associated with its ability to inhibit bacterial protein synthesis through reversible binding to the 50S subunit of the bacterial ribosome, thereby interfering with peptide-chain elongation. Although erythromycin exhibits activity against several Gram-positive and certain Gram-negative bacteria, its effectiveness depends on the susceptibility profile of the causative organism, the site of infection, and the development of antimicrobial resistance.
Erythromycin has established applications in the treatment of pertussis, an acute respiratory infection caused by Bordetella pertussis. Administration of macrolide antibiotics can reduce bacterial carriage and transmission, particularly when treatment is initiated during the early stages of infection. Erythromycin has also been used against infections caused by Streptococcus pneumoniae, including selected respiratory tract infections, provided that the isolate remains susceptible. However, increasing macrolide resistance among pneumococcal populations has restricted its empirical use in several clinical settings.
Another important indication involves infections associated with Corynebacterium diphtheriae, the bacterium responsible for diphtheria. Erythromycin may be administered to eliminate the organism and limit transmission, alongside appropriate antitoxin therapy and supportive management when clinically indicated. Its application in syphilis, caused by Treponema pallidum, is primarily historical or restricted to exceptional circumstances because erythromycin is not considered a reliable contemporary treatment option. Penicillin remains the preferred therapy for syphilis, while alternative regimens should be selected according to current clinical guidelines and patient-specific considerations.
Erythromycin also demonstrates activity against selected enteric pathogens, including Campylobacter species, which can cause inflammatory gastroenteritis and diarrheal illness. Nevertheless, treatment is generally reserved for clinically appropriate cases, particularly severe infections or patients at increased risk of complications. Supportive care remains central to the management of uncomplicated infectious diarrhea, and antimicrobial selection should reflect local resistance patterns and established treatment recommendations.
Beyond conventional bacterial pathogens, erythromycin exhibits activity against certain atypical microorganisms, including Mycoplasma species and Chlamydia species. These organisms possess biological characteristics that distinguish them from typical extracellular bacteria, making antibiotics that target cell-wall synthesis ineffective against some of them. However, erythromycin is not the preferred agent for every infection caused by these organisms, and treatment recommendations vary according to the specific pathogen, anatomical site, pregnancy status, and patient characteristics.
Compared with erythromycin, newer macrolides, particularly clarithromycin and azithromycin, offer pharmacokinetic advantages and differences in antimicrobial coverage. Azithromycin achieves substantial tissue concentrations and has a prolonged elimination half-life, whereas clarithromycin demonstrates activity against selected respiratory pathogens and certain mycobacteria. Clarithromycin-containing combinations have applications in the treatment of Helicobacter pylori infection and selected nontuberculous mycobacterial diseases, depending on susceptibility and current guidelines.
Some macrolides also have specialized roles in treating infections associated with intracellular pathogens and protozoa. For example, azithromycin may be included in selected combination regimens for toxoplasmosis in particular clinical circumstances, although it is not a universal first-line treatment. Erythromycin remains clinically relevant for specific susceptible infections, but its use requires consideration of antimicrobial resistance, gastrointestinal intolerance, drug interactions, and potential cardiac effects. Rational prescribing and microbiological assessment are therefore essential to maximize therapeutic efficacy and minimize avoidable adverse outcomes.
Spectrum of activity of erythromycin
Erythromycin is inhibits bacterial protein synthesis by binding reversibly to the 50S subunit of the bacterial ribosome. Its antimicrobial spectrum encompasses selected Gram-positive bacteria and certain Gram-negative bacteria, as well as some atypical bacterial pathogens. The extent of its activity depends on the bacterial species, the susceptibility of the organism, the drug concentration at the site of infection, and the prevalence of acquired resistance mechanisms.
Erythromycin is predominantly bacteriostatic, meaning that it suppresses bacterial growth and multiplication rather than directly killing bacterial cells. However, its effect may become bactericidal against particular susceptible organisms under specific conditions, including adequate drug concentrations and sufficient exposure. This distinction demonstrates that the antimicrobial action of erythromycin is not uniform across all bacterial species.
Among Gram-positive bacteria, erythromycin exhibits activity against susceptible strains of Streptococcus pyogenes, Streptococcus pneumoniae, and certain staphylococci. These organisms are associated with infections of the respiratory tract, skin, and soft tissues. Nevertheless, resistance among streptococci and staphylococci can substantially limit treatment effectiveness, making susceptibility testing important when resistance is suspected or local resistance rates are high.
The activity of erythromycin against Gram-negative bacteria is comparatively restricted. Some organisms, including Bordetella pertussis, Legionella pneumophila, and Campylobacter jejuni, may be susceptible and are relevant to specific respiratory or gastrointestinal infections. Erythromycin also has activity against certain atypical pathogens, including Chlamydia trachomatis and Mycoplasma pneumoniae. These organisms differ from typical bacteria in their biological characteristics, which influences their response to antimicrobial agents.
The spectrum of erythromycin is limited against many Enterobacterales, including Escherichia coli and Klebsiellaspecies, as well as several non-fermenting Gram-negative bacilli. Its usefulness is also compromised by resistance mechanisms such as ribosomal target modification, commonly mediated by erm genes, and active drug efflux, which may be associated with mef genes. These mechanisms reduce intracellular antibiotic activity and can result in clinical treatment failure.
Erythromycin should not be considered universally broad-spectrum. Its clinical value lies in its activity against selected susceptible pathogens rather than comprehensive coverage of Gram-positive and Gram-negative bacteria. Appropriate selection requires consideration of the suspected pathogen, infection site, local resistance patterns, and microbiological findings. This targeted approach supports effective antimicrobial therapy while reducing unnecessary antibiotic exposure and the selection of resistant bacterial populations.
Mechanism or mode of action of erythromycin
Erythromycin exerts its antibacterial effect by interfering with protein synthesis in susceptible bacteria. Its principal molecular target is the 50S subunit of the bacterial ribosome, where it interacts with the peptidyl transferase centre region and, particularly, the 23S ribosomal ribonucleic acid (23S rRNA). This interaction disrupts the normal progression of translation, thereby limiting the production of proteins required for bacterial growth, cellular maintenance, and replication.
The antibacterial activity of erythromycin begins with its reversible association with the 50S ribosomal subunit. Bacterial ribosomes consist of two structural components, the 30S and 50S subunits, which work together to translate messenger RNA (mRNA) into polypeptide chains. During this process, transfer RNA (tRNA) molecules deliver amino acids to the ribosome, where successive amino acids are incorporated into a growing protein chain. Erythromycin interferes with this coordinated sequence by binding within the nascent peptide exit tunnel of the 50S subunit, thereby obstructing the movement of newly synthesized polypeptides through the ribosome.
A major consequence of this interaction is the disruption of peptide-chain elongation. Although erythromycin is not primarily characterized as a direct inhibitor of peptidyl transferase catalytic activity, its binding can interfere with peptide-bond formation and the progression of the growing polypeptide chain, depending on the sequence of the nascent peptide and the structural context of the ribosome. Translation may be arrested at particular stages, preventing the efficient completion of protein synthesis. This interruption reduces the availability of essential bacterial proteins and compromises processes necessary for normal cellular function.
Erythromycin also affects the translocation stage of translation. Translocation involves the coordinated movement of the ribosome along the mRNA molecule, accompanied by the repositioning of tRNA molecules between ribosomal binding sites. This movement enables the next codon to enter the decoding region and allows the addition of subsequent amino acids to the developing polypeptide. By obstructing the peptide exit tunnel and altering ribosomal dynamics, erythromycin can impair this progression and promote translational arrest. The resulting inhibition prevents susceptible bacteria from maintaining the normal rate and continuity of protein production.
Under usual therapeutic conditions, erythromycin is predominantly bacteriostatic, meaning that it suppresses bacterial growth and multiplication rather than directly causing rapid bacterial destruction. However, its activity may vary according to the bacterial species, antimicrobial concentration, susceptibility profile, and infection site. Its effectiveness therefore depends on adequate drug exposure and the sensitivity of the target organism.
Resistance can develop through several mechanisms, including methylation of the 23S rRNA binding region, modification of ribosomal targets, active drug efflux, and certain ribosomal mutations. These changes reduce erythromycin binding or decrease its intracellular concentration, thereby weakening its inhibitory effect. Erythromycin acts primarily through reversible binding to the bacterial 50S ribosomal subunit, disrupting translation and restricting the synthesis of proteins essential for bacterial growth and proliferation.
Bacterial resistance to erythromycin
Bacterial resistance to erythromycin arises through several molecular and cellular mechanisms that reduce the susceptibility of microorganisms to this macrolide antibiotic. Erythromycin exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, particularly the 23S ribosomal RNA (rRNA), thereby interfering with protein synthesis and inhibiting bacterial growth. However, resistant bacteria can develop adaptive mechanisms that diminish the drug’s intracellular concentration, modify its ribosomal target, or enzymatically inactivate the antibiotic. These processes can compromise treatment effectiveness and contribute to the persistence of bacterial infections.
One important mechanism involves the active efflux of erythromycin from bacterial cells. Efflux systems are membrane-associated transport proteins that recognize and expel antimicrobial agents, reducing their intracellular accumulation to concentrations necessary for effective inhibition. In susceptible bacteria, erythromycin can reach its ribosomal target and interfere with protein synthesis. In resistant organisms, increased expression or activity of efflux pumps can accelerate drug removal, lowering its effective concentration within the cell.
This mechanism is particularly significant in certain Gram-positive bacteria, including Staphylococcus species, and is frequently associated with genes such as msr and mef, depending on the organism and resistance phenotype. Another major mechanism is modification of the antibiotic-binding site within the bacterial ribosome. This process commonly involves methylation of specific nucleotides in domain V of the 23S rRNA, mediated by erythromycin ribosomal methylase genes, collectively designated erm. Methylation alters the structural characteristics of the ribosomal target and reduces erythromycin’s binding affinity.
The antibiotic becomes less effective at inhibiting translation, allowing bacterial protein synthesis to continue despite exposure to the drug. Depending on the resistance determinant, this mechanism may also confer cross-resistance to other macrolides, lincosamides, and streptogramin B antibiotics, a phenotype commonly described as MLSB resistance. Enzymatic inactivation represents an additional pathway through which bacteria can develop erythromycin resistance. Certain microorganisms produce enzymes, including esterases or phosphotransferases, that chemically modify or degrade the antibiotic, reducing its biological activity.
Mutations affecting ribosomal components or regulatory pathways may contribute to altered susceptibility in particular bacterial populations. The distribution of these resistance determinants varies among bacterial species and is influenced by antimicrobial exposure, horizontal gene transfer, and selective pressure. Inappropriate prescribing, unnecessary antibiotic use, and incomplete adherence to prescribed treatment can promote the selection and dissemination of resistant strains.
Pharmacokinetics of erythromycin
Erythromycin is a macrolide antibiotic whose pharmacokinetic profile is influenced by its chemical stability, pharmaceutical formulation, gastrointestinal absorption, tissue distribution, and routes of excretion. The drug is susceptible to degradation in the acidic environment of the stomach, which can reduce the amount of active compound available for systemic absorption following oral administration. Its oral bioavailability varies according to the formulation used, with enteric-coated preparations and acid-resistant derivatives developed to improve drug stability during gastrointestinal transit.
Oral erythromycin is available in several formulations, including erythromycin base, stearate, estolate, and ethylsuccinate. These preparations differ in their acid stability, dissolution characteristics, and absorption profiles. Erythromycin stearate and ethylsuccinate are commonly used to facilitate oral administration, while the estolate formulation provides improved acid stability. Nevertheless, the extent and rate of absorption may vary with the specific preparation and the presence of food in the gastrointestinal tract.
Administration instructions therefore depend on the formulation; certain products are best taken on an empty stomach, whereas others may be taken with food to improve gastrointestinal tolerance or according to their product-specific guidance. Following absorption, erythromycin undergoes widespread distribution into various body tissues and fluids. Therapeutically relevant concentrations may be achieved in tissues such as the lungs, liver, tonsils, and prostate, supporting its use against susceptible bacterial pathogens at these sites. However, penetration into the cerebrospinal fluid (CSF) is generally poor, even when the meninges are inflamed.
This limited central nervous system distribution restricts its suitability for treating infections within the CSF. Erythromycin also crosses the placenta and can enter breast milk, considerations that may be relevant when evaluating its use during pregnancy and lactation. Erythromycin is metabolized primarily in the liver, where hepatic enzyme activity contributes to its biotransformation and potential interactions with other medications. The drug and its metabolites are eliminated predominantly through the biliary system into the intestinal tract, with much of the administered dose subsequently appearing in faeces.
Urinary excretion accounts for a comparatively smaller proportion of elimination, although the extent varies with the formulation and individual pharmacokinetic conditions. Erythromycin’s disposition is characterized by formulation-dependent oral absorption, extensive tissue distribution, limited CSF penetration, hepatic metabolism, and predominantly biliary elimination. These characteristics influence its dosing requirements, therapeutic distribution, and potential for drug interactions. Its use should therefore follow formulation-specific prescribing information to achieve appropriate exposure while minimizing adverse effects.
Side effects / toxicity of erythromycin
Erythromycin is a macrolide antibiotic whose pharmacokinetic profile is influenced by its chemical stability, pharmaceutical formulation, gastrointestinal absorption, tissue distribution, and routes of excretion. The drug is susceptible to degradation in the acidic environment of the stomach, which can reduce the amount of active compound available for systemic absorption following oral administration. Its oral bioavailability varies according to the formulation used, with enteric-coated preparations and acid-resistant derivatives developed to improve drug stability during gastrointestinal transit.
Oral erythromycin is available in several formulations, including erythromycin base, stearate, estolate, and ethylsuccinate. These preparations differ in their acid stability, dissolution characteristics, and absorption profiles. Erythromycin stearate and ethylsuccinate are commonly used to facilitate oral administration, while the estolate formulation provides improved acid stability. Nevertheless, the extent and rate of absorption may vary with the specific preparation and the presence of food in the gastrointestinal tract.
Administration instructions therefore depend on the formulation; certain products are best taken on an empty stomach, whereas others may be taken with food to improve gastrointestinal tolerance or according to their product-specific guidance. Following absorption, erythromycin undergoes widespread distribution into various body tissues and fluids. Therapeutically relevant concentrations may be achieved in tissues such as the lungs, liver, tonsils, and prostate, supporting its use against susceptible bacterial pathogens at these sites. However, penetration into the cerebrospinal fluid (CSF) is generally poor, even when the meninges are inflamed.
This limited central nervous system distribution restricts its suitability for treating infections within the CSF. Erythromycin also crosses the placenta and can enter breast milk, considerations that may be relevant when evaluating its use during pregnancy and lactation. Erythromycin is metabolized primarily in the liver, where hepatic enzyme activity contributes to its biotransformation and potential interactions with other medications. The drug and its metabolites are eliminated predominantly through the biliary system into the intestinal tract, with much of the administered dose subsequently appearing in faeces.
Urinary excretion accounts for a comparatively smaller proportion of elimination, although the extent varies with the formulation and individual pharmacokinetic conditions. Erythromycin’s disposition is characterized by formulation-dependent oral absorption, extensive tissue distribution, limited CSF penetration, hepatic metabolism, and predominantly biliary elimination. These characteristics influence its dosing requirements, therapeutic distribution, and potential for drug interactions. Its use should therefore follow formulation-specific prescribing information to achieve appropriate exposure while minimizing adverse effects.
References
Platon, V.-M., Dragoi, B., & Marin, L. (2022). Erythromycin formulations—A journey to advanced drug delivery. Pharmaceutics, 14(10), Article 2180.
Hoyt, J. C., & Robbins, R. A. (2001). Macrolide antibiotics and pulmonary inflammation. FEMS Microbiology Letters, 205(1), 1–7.
Chung K.T, Stevens Jr., S.E and Ferris D.H (1995). A chronology of events and pioneers of microbiology. SIM News, 45(1):3–13.
Drusano G.L (2007). Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis, 45(suppl):89–95.
Finch R.G, Greenwood D, Norrby R and Whitley R (2002). Antibiotic and chemotherapy, 8th edition. Churchill Livingstone, London and Edinburg.
Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001.
Katzung, B. G. (2003). Basic and Clinical Pharmacology (9th ed.). NY, US, Lange.
Discover more from Microbiology Class
Subscribe to get the latest posts sent to your email.
